
Reset all filters
01 3Aiphagan
02 14Alphagan/Combigan
03 1Lumify
Brimonidine Tartrate, Timolol Maleate
Main Therapeutic Indication : Ophthalmology
Currency : USD
2020 Revenue in Millions : 326
2019 Revenue in Millions : 0
Growth (%) : 100
Main Therapeutic Indication : Ophthalmology
Currency : USD
2020 Revenue in Millions : 326
2019 Revenue in Millions : 0
Growth (%) : 100
Brimonidine Tartrate, Timolol Maleate
Main Therapeutic Indication : Ophthalmology
Currency : USD
2021 Revenue in Millions : 529
2020 Revenue in Millions : 326
Growth (%) : 62
Main Therapeutic Indication : Ophthalmology
Currency : USD
2021 Revenue in Millions : 529
2020 Revenue in Millions : 326
Growth (%) : 62
Brimonidine Tartrate, Timolol Maleate
Main Therapeutic Indication : Ophthalmology
Currency : USD
2022 Revenue in Millions : 346
2021 Revenue in Millions : 529
Growth (%) : -35
Main Therapeutic Indication : Ophthalmology
Currency : USD
2022 Revenue in Millions : 346
2021 Revenue in Millions : 529
Growth (%) : -35
Brimonidine Tartrate, Timolol Maleate
Main Therapeutic Indication : Ophthalmology
Currency : USD
2023 Revenue in Millions : 272
2022 Revenue in Millions : 346
Growth (%) : -21
Main Therapeutic Indication : Ophthalmology
Currency : USD
2023 Revenue in Millions : 272
2022 Revenue in Millions : 346
Growth (%) : -21
Brimonidine Tartrate, Timolol Maleate
Main Therapeutic Indication : Ophthalmology
Currency : USD
2024 Revenue in Millions : 248
2023 Revenue in Millions : 272
Growth (%) : -9
Brimonidine Tartrate, Timolol Maleate
Main Therapeutic Indication : Ophthalmology
Currency : USD
2017 Revenue in Millions : 552
2016 Revenue in Millions : 546
Growth (%) : 1